Nolato AB
STO:NOLA B
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
41.1485
62.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Nolato AB
You don't have any saved screeners yet
Welcome to the Nolato Q2 2022 Report. [Operator Instructions]
Today, I am pleased to present Christer Wahlquist, the CEO; and Per-Ola Holmstrom, the CFO. Please begin your meeting.
Welcome to the presentation of Nolato's second quarter 2022. This is Christer Wahlquist speaking. And beside me, I have Per-Ola Holmstrom. Starting on Page 2. We can conclude that we have had a quarter with increasing sales in Swedish currency, amounting to approximately SEK 2.9 billion. However, we saw a decrease by 6% if we adjust for currency effects.
The second quarter was affected by external factors such as COVID, supply chain issues, and the war in Ukraine. So that together, created a profit and EBITA level of SEK 264 million in comparison to SEK 336 million in the second quarter of 2021. That gives an EBITA margin of 9.1 percentage points. And that margin was then, of course, affected by volumes, a lot on the cost inflation side and production efficiency due to lack of components and supply chain issues.
Cash flow during the quarter ended up at SEK 18 million and it was low because of increased working capital requirements, but Per-Ola will come back to that a little bit later in the presentation.
Turning to Page 3, summarizing up the Nolato Group and the 3 different business areas that build the group. The 3 different business areas are creating synergies by using the same technology and the same business models. But in different market segments, giving competitive advantages by cross utilizing the different markets towards our customers.
On Page 4, we start with the business area medical solutions. This business area has had a -- been on a growth journey, building a global solution for leading pharma and medtech companies. And on the graph, you will see the 20-year sales growth for the company. We have had a long period of strong organic growth and also then combined with some acquisitions during the period.
On Page 5, we have the different product areas that is key for us, the In Vitro Diagnostic corresponding to approximately 18% of the total. That is a growth market, a long-term growth market with very high volumes and very interesting to be part of. The second one is then Cardiology, which is, of course, implants, lifetime implants, doing things around your heart. That corresponds to approximately 7% of our sales.
Pharma Packaging is the containers and for liquid and solid drugs. Continence Care is a large volume area, it corresponds to approximately 12% of our total sales. Endoscopy & General Surgery. It's the cervical part of the business that was heavily increased when we acquired GW Plastics in the United States.
It's been on a situation with some lower volumes during COVID, but it's now picking up. And the last one that we are highlighting is the Drug Delivery, which is then the Drug Delivery systems for drugs that needs to be injected slowly to your body, corresponds to approximately 15% of the total sales for Medical Solutions.
Turning to Page 6, highlighting the second quarter for Medical Solutions. During the quarter, we saw a 19% increase in sales, but -- if we adjust that for currency, it corresponds to 8% increase. During the quarter, we have seen inflation on our cost side, and we have been able to move that on to transfer that to our customers. But of course, creating then growth not in volume, but in sales. We have had a situation where we are a little bit behind on those increases affecting our margin.
So the margin ended up at 10%. That was, of course, we saw during the quarter that we still had a little bit lower sales on the IVD sector and higher on the cervical side, affecting the margin. We saw rising material costs and it's offset by the increasing price towards our customers, but with some time lag. And of course, some cost impact of the capacity investments made in 2021. So the quarter ended up at just above SEK 1.2 billion in sales and an operating profit of SEK 121 million.
If we move to Page 7, starting with Integrated Solutions. In this business area, it used to be a telecom business area, but for a certain number of years now, we have expanded ourselves into new market segments, creating substantial growth over the last 5, 6 years.
If we then look on Page 8 and looking at the different parts of the business area, we have 2 large divisions in this business area. We have the EMC and Thermal business that is shown on the right side of this picture. And we have the Consumer Electronics part of the business area shown on the left side of the page of this picture. So here, you see some examples of what we are working on and those kind of things.
If we turn to Page 9, focusing on second quarter for Integrated Solutions. We saw during the quarter a 14% decrease in sales, but if we adjust that for currencies, it was a decrease of 25%. We saw that end-customer demand was negatively reflected by the situation in Eastern Europe.
And we also saw that the EMC part of this business area continued to perform well and ended up at SEK 170 million sales. We expect sales in the third quarter to be around 25% lower than the second quarter this year, but we should remember that sales in the second quarter was affected by a late delivery of approximately SEK 100 million that was supposed to be delivered in the third quarter, affecting those and making them a little bit more even. The EBITA margin of 10.7% was, of course, affected by the lower volumes. So the quarter ended up just above SEK 1 billion in sales and an operating profit of SEK 109 million.
If we turn to Page 10, focusing on Industrial Solutions. With this business area, we are in the technological and the geographical expansion journey and building a footprint in the 3 important continents.
If we turn then to Page 11, focusing on the 2 parts of the business area, Industrial Solutions. We have 1 part, a larger portion, called General Industry focusing on large industrial customers and supporting them with the design and development and afterwards production. The second part of the business area is Automotive, and here, we focus mainly on the Scandinavian automotive market, both heavy vehicles and cars.
Turning to Page 12, focusing on second quarter for Industrial Solutions. During the quarter, we saw a 17% increase in sales. Adjusted for currency, it ended up a 10% increase. But the volumes was in level with last year.
So it's the increase is coming from the charging of higher costs and then contributing to the positive growth of the sales. We saw component shortages, mainly in the Automotive, affecting our deliveries to our customers. The margin ended up at 5.5 percentages, and that was affected by fluctuating call-offs order resulting in the lower production efficiency and also a time lag in charging on the cost increases for our customers. So the quarter ended up at SEK 676 million with an operating profit of SEK 37 million.
Good afternoon, Per-Ola Holmstrom to comment on group financial numbers on Page 13. Net sales increased in the quarter, but currency effects stood for SEK 290 million and charging on higher costs contributed additionally. Sales ended up for the group of SEK 2.9 billion compared to SEK 2.786 billion Q2 last year. The EBITA margin was adverse with 3.0% compared to Q2 last year being 9.1%. The lower margin affected all profit levels negatively. Operating profit, EBITA, excluding a nonrecurring item last year was SEK 264 million compared to SEK 336 million last year.
Last year, Q2 had a nonrecurring item of SEK 50 million from a U.S. pandemic loan being waived. Cash flow after investments was SEK 18 million compared to SEK 346 million. The decrease of cash flow is mainly because of higher working capital requirements compared to last year. Like in Q1, depending on generally less use of supplier finance for trade receivables.
For a large customer, we get paid in 10 to 20 days, but pay our suppliers in 90 days. when flat or decreasing sales, we have delayed effect of negative impact of working capital. Net investments affecting cash flow is lower than last year in the quarter, SEK 113 million compared to SEK 154 million.
Full year CapEx last year 2021 was SEK 782 million. We have decided to acquire real estate within Medical in Sweden to secure future expansion of the Medical business. The purchase price is SEK 150 million. Payment is depending on some formalities but expected around the end of the year. Depending on the date, we expect CapEx to be between SEK 600 million to SEK 750 million for the full year 2022.
Net financial liabilities were SEK 640 million. We have a sustained strong financial position with interest-bearing liabilities of only 0.7x of our run rate of EBITA results.
Turning to Page 14, focusing on the current situation per business area. On the Medical Solutions, we have a maintained growth strategy, A lot of focus on innovation based on our strong customer relationships, but the business is impacted by the pandemic.
Integrated Solutions, we have established position in new product areas. We have based this on our flexible production structure. We also see the 5-year rollout and new initiatives for the automotive sector that are positive for our EMC business. The business area at large are impacted by the geopolitical situation.
On Industrial Solutions, we have advanced our market positions, but are impacted by supply chain disruptions, and we are emphasizing sustainable solutions.
Thank you. We are now opening up for questions.
[Operator Instructions] Our first question comes from the line of Adrian Gilani of ABG.
It's Adrian here at ABG. I'd like to start off with a question regarding the Integrated Solutions guidance for Q3. And basically, do you expect to be able to maintain similar margins as Q2 despite the 25% quarter-over-quarter decline in sales?
We do think that should have a slightly negative impact of the margins being such a high decrease compared to this quarter, but not very much.
Okay. And also, I see no mention of component shortages in VHP, but rather our focus seems to be on lost sales in Eastern Europe. Should we take this to mean that the bottleneck is now not on the supply side at all, but rather that demand is entirely the issue?
Yes, that is correct.
Okay. And also in Medical Solutions, you mentioned several reasons for the year-over-year margin decline. You mentioned capacity utilization lag effect on moving on costs and also the sales mix. Are you able to sort of quantify how much these affected the margin and which one was the major reason for the margin decline?
Those 3 is a combination. And we do see that they are standing for quite similar effects on the margin. Maybe the CapEx utilization effect is less than the other 2.
Okay. And also, we've seen -- 2 quarters in a row, right, where we -- where you have mentioned weaker IVD sales. Is it reasonable to assume that we should start seeing more positive sort of restocking effects among customers going forward?
The end market for IVD is picking up. And of course, then there is a long tail of different supplies in between. But of course, it's more question of time than anything else, but we don't have an exact date because these stock levels are in different parts of the supply chain.
Okay. And also just sort of a general question on cost inflation. We saw the inflation rate continue to accelerate during Q2. So where are you sort of now in terms of further price increases towards customers? When you say that you're keeping up with the inflation rate? Or should we expect continued lag effects in Q3 as well?
That would depend on if prices continue to rise during the quarter, then we will continue to have the lag effect. So we will catch up when we sort of that increase is evening out to a more constant level. And then, of course, if it goes down in any areas, then we will gain on the going down with the same kind of lag effect.
Okay. But it does take you roughly 1 quarter to catch up if costs stay roughly the same? Is that reasonable?
I would not say -- it depends on when the growth is decreasing on the inflation side. And the total I will not say that we are a quarter behind in our price increases, but it's been constantly increasing for a long period of time.
Okay. And the final question from my side. I'll try my luck with this one. Is there any news or any update you can give us in regards to the dual sourcing in VHP?
We have noted in the report today that we do see one effect of dual sourcing in Q3 and the second half of 2022. So that is a conclusion. I think you are looking for.
Our next question comes from the line of Carl Ragnerstam of Nordea.
It's Carl here from Nordea. A follow-up a bit here on the dual sourcing. Is it possible to quantify, I mean, adding back the SEK 100 million in large order, it's down 11% sequentially, I guess, in Q3. Is it possible to give the dynamics behind it, how much would you say is dual sourcing? And also, will it be sort of worse going into Q4? Or have we seen the full effect of the dual sourcing already in Q3, would you say?
We do estimate that volumes and sales have reached or will reach the lowest level at the level we indicate for Q3, even including dual sourcing effects. So it's sort of flattening out as we estimate right now.
Okay. So you don't expect it to get worse in Q3. What do you know today at least yes?
No.
Okay. That's super helpful. And could you also update us on your chances of winning new contracts with BAT, I guess, I think you said previously that it could be announced after the summer. Is it someone else who want that contract? Or is it -- yes?
We have ongoing discussions with our customer in this second part of the business area. And we will -- we are not judging that it will affect the volumes during 2022.
Okay. But potentially in '23, in that if you ramp up it -- yes. Okay. Very good. And also -- the margin in Industrial Solutions is -- I mean, the 5.5% is not far away from the first COVID level.
I mean, have you implemented action plan there to sort of bring up the margins again? Or do you expect it to sort of normalize now that we see or hear at least at the automotive players that the production pace is starting to be more stable.
I think the margin -- the low margin is, of course, twofold. One is being a little bit behind on -- or the time effect of increasing prices. And you saw -- you heard in our presentation that it's substantial effect of that. And that other part is, of course, the sluggish volumes from our customer during the supply chain issues. So I think as soon as those two sort of external factor, so to say, are away, then we will get back to a more normal level of our profit.
And you don't see that so far?
We see -- still see some volatility on our customers' demand. And we have not seen sort of leveling out on the total picture for the cost increases.
[Operator Instructions] And there are no further questions at this time. Please go ahead, speakers.
Thank you very much for your interest in Nolato and the presentation of our second quarter. I hope you all get a very nice summer, and we'll see you later on again. Thank you very much.